SEPN’s SEP-479 phase I data expected in Q1 next year
SEP-479, an oral PTH receptor agonist, is advancing with phase I data expected in Q1 next year. The program targets improved calcium control and patient adherence, with additional updates for Graves’, osteoporosis and mast cell diseases.